Progyny's Profit Has Grown While Its Valuation Has Contracted

Progyny presents a useful example of how a stock can become cheaper even while the business grows. Over the three years examined in the original analysis, the shares fell 27.4%, while the company's diluted share count declined and trailing profit increased.

The valuation change is large. The analysis calculates that Progyny's price-to-earnings ratio fell from 75.6 three years ago to 28.4. Diluted shares declined from about 101 million to 82.1 million, partly reflecting repurchases. Trailing net income rose to $78.6 million from $49.3 million. A lower stock price, fewer shares and higher profit all pushed the multiple down.

The latest reported quarter supports the profit trend. Second-quarter 2026 revenue was $350.5 million, up 5.3% from $332.9 million a year earlier. Gross profit rose 13% to $89.3 million, and gross margin increased to 25.5% from 23.7%. Net income climbed to $28.1 million from $17.1 million. Excluding a departed large client that contributed $17.2 million in the prior-year quarter, revenue grew 11%.

Some of the earnings improvement came from lower stock-based compensation as well as operating leverage. That matters because a shareholder should distinguish recurring service economics from expense changes that may not continue at the same rate. Operating cash flow for the trailing 12 months was $201.2 million, roughly flat with the prior-year comparison, even as reported net income rose.

The company's balance sheet provides flexibility. Progyny reported $236.9 million of cash, equivalents and marketable securities at June 30 and no debt. It also repurchased more than two million shares under its current authorization. Buybacks add value when the business remains healthy and the purchase price is sensible, but they do not replace organic growth.

Client retention and utilization are the central operating variables. Progyny sells fertility and broader family-building benefits to employers, so revenue depends on covered lives, renewal decisions and member use. Management said early selling-season commitments were running ahead of the prior year and that it had removed most retention risk among its largest accounts. Those are encouraging statements, but reported enrollment and revenue will test them.

A 28.4-times trailing multiple is far below the stock's earlier level, yet it is not automatically cheap. The current valuation assumes that Progyny can keep adding clients, sustain gross-margin improvement and avoid another large-account loss. If revenue growth stays in the mid-single digits while profit growth slows, the multiple may still look demanding. If client growth reaccelerates and margin gains persist, the lower share count gives each remaining share a larger claim on earnings.

The next earnings report should be judged less by a one-day price reaction than by three numbers: organic revenue growth excluding lost clients, gross margin and covered lives for the coming benefit year.